SHELTON, Conn., Oct. 26, 2017 /PRNewswire/ -- NanoViricides, Inc.
(NYSE American: NNVC (the
"Company") announced today that it has extended its agreement with
SUNY Upstate Medical Center for further
testing of its nanoviricides® drug candidates against
varicella-zoster virus (VZV), the shingles virus, that causes
debilitating infection of human skin.
The Company will conduct additional studies in order to finalize
the candidates for clinical drug development, and to obtain
IND-enabling pre-clinical data, under the extension. The final
candidate is expected to undergo toxicology and safety studies
leading to IND submission to the FDA for the treatment of shingles
in humans.
The Company has previously reported that the nanoviricides® drug
candidates showed marked inhibition of VZV infection, replication
and spread in human skin cultured ex vivo, over the time course of
VZV infection.
Since VZV causes skin lesions, experimental VZV infection of
human skin is considered to be representative of natural VZV
infection. VZV is restricted to human tissue and only infects
and replicates in human tissue. Dr. Moffat runs the leading
laboratory studying disease-relevant models of VZV infection of
human skin for evaluating effectiveness of potential drugs against
the shingles virus.
Dr. Moffat is an internationally recognized expert on
varicella-zoster virus, and her research has focused on the
pathogenesis and treatment of diseases caused by this virus.
The National Institutes of Health has a contract with Dr. Moffat's
lab for evaluating anti-viral compounds against VZV. She is
the director of two research core facilities at SUNY Upstate: the
Center for Humanized Mouse Models and In vivo Imaging.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage
company that is creating special purpose nanomaterials for
antiviral therapy. The Company's novel nanoviricide® class of drug
candidates are designed to specifically attack enveloped virus
particles and to dismantle them. The Company is developing drugs
against a number of viral diseases including VZV, oral and genital
Herpes, viral diseases of the eye including EKC and herpes
keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza,
HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among
others.
This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Actual events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities.
Although it is not possible to predict or identify all such
factors, they may include the following: demonstration and proof of
principle in pre-clinical trials that a nanoviricide is safe and
effective; successful development of our product candidates; our
ability to seek and obtain regulatory approvals, including with
respect to the indications we are seeking; the successful
commercialization of our product candidates; and market acceptance
of our products.
View original content with
multimedia:http://www.prnewswire.com/news-releases/excellent-results-in-inhibiting-shingles-virus-in-human-skin-nanoviricides-extends-agreement-with-suny-upstate-medical-center-300543762.html
SOURCE NanoViricides, Inc.